COO vs JNJ
COO: A global medical device leader operating at the intersection of vision care and women's health through its CooperVision and CooperSurgical divisions. JNJ: A global healthcare leader spanning pharmaceuticals, medical devices, and consumer health products, with a portfolio spanning acute care, oncology, immunology, cardiovascular, and infectious disease.
Side-by-side fundamentals
| Metric | COO | JNJ | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $70.50 | $255.63 | |
| Market cap as of 2026-07-23 | $13.9B | $614.6B | |
| P/E as of 2026-07-23 | 58.76 | 29.22 | JNJ lower |
| PEG as of 2026-07-23 | 6.73 | 3.16 | JNJ lower |
| Net margin as of 2026-07-23 | +5.6% | +21.5% | JNJ higher |
| Gross margin as of 2026-07-23 | +65.5% | +68.0% | JNJ higher |
| Operating margin as of 2026-07-23 | +11.8% | +25.7% | JNJ higher |
| ROE as of 2026-07-23 | +2.8% | +26.3% | JNJ higher |
| ROA as of 2026-07-23 | +1.9% | +10.7% | JNJ higher |
| Debt / equity as of 2026-07-23 | 0.30 | 0.68 | COO lower |
| Revenue growth (YoY) as of 2026-07-23 | +6.1% | +8.1% | JNJ higher |
| Revenue CAGR (3y) SEC XBRL | +7.3% | +6.2% | COO higher |
| Dividend yield as of 2026-07-23 | +0.0% | +2.1% | JNJ higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-07-23 | 0.82 | 0.23 | |
| 1-year return as of 2026-07-22 close | -3.5% | +52.2% | JNJ higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.